# Shelley Hartman

> Shelley Hartman is the co-founder and chief executive officer of Aegle Therapeutics, a Woburn, Massachusetts clinical-stage biotechnology company developing therapies based on extracellular vesicles derived from mesenchymal stem cells. She brought nearly two decades of healthcare and life-sciences investment banking experience, including seven years as a Goldman Sachs managing director, to the work of licensing university science, financing a small biotech and moving its lead program into clinical development.

- **Role:** Co-Founder and Chief Executive Officer at Aegle Therapeutics
- **Organizations:** Aegle Therapeutics, LifeSync Corporation, GMP Companies, Goldman Sachs, First Boston, University of Miami Miller School of Medicine
- **Education:** B.A., Wellesley College
- **Known for:** Built a nineteen-year career in healthcare and life-sciences investment banking, including seven years as a Goldman Sachs managing director., Led the medical-device startup LifeSync Corporation as chairman and CEO., Co-founded Aegle Therapeutics around licensed University of Miami technology and became its full-time CEO in 2019.

## Career timeline

- **1986-1994** — Worked at First Boston, focused on life-sciences and healthcare-services investment banking.
- **1994-2004** — Worked at Goldman Sachs; spent her final seven years there as a managing director serving healthcare and life-sciences clients.
- **2004** — Was recruited to Florida to run LifeSync Holdings/GMP Companies, an incubator for biopharma, medical-technology and diagnostic products.
- **2014-2017** — Served as an entrepreneur-in-residence at the University of Miami Miller School of Medicine.
- **2019-present** — Joined Aegle Therapeutics full-time as chief executive officer after helping license technology developed from University of Miami research.

## Achievements

- Built a nineteen-year career in healthcare and life-sciences investment banking, including seven years as a Goldman Sachs managing director.
- Led the medical-device startup LifeSync Corporation as chairman and CEO.
- Co-founded Aegle Therapeutics around licensed University of Miami technology and became its full-time CEO in 2019.
- Led Aegle as it advanced its extracellular-vesicle platform into early-stage clinical development.
- Represented Aegle as a speaker at industry forums including BioFuture and BIO International Convention programming.

## Latest updates

- **2026-06** — BIO International Convention listed Hartman for a panel on patient-centric clinical development and regulatory pathways in rare-disease therapeutics.
- **2026-03** — Hartman signed Aegle’s SEC Form D for a $700,000 offering in which $455,695 had been sold to ten investors.
- **2025-10** — Aegle announced Hartman as a speaker on a rare-disease therapies panel at BioFuture 2025 in New York.
- **2025-03** — New World Angels announced a $697,500 convertible-note investment in Aegle; Hartman said investor support was critical to advancing the company into the clinic.

## Links

- Website: https://aegletherapeutics.com/
- LinkedIn: https://www.linkedin.com/in/shelley-hartman-75039135

---

Profile page: https://yespress.io/shelley-hartman
Published by YesPress — https://yespress.io
Last updated: 2026-08-27